Abemaciclib and letrozole in ER positive rare ovarian cancer (ALEPRO)

The results of large randomized phase 3 trials of the combination of an aromatase inhibitor combined with an CDK4/6 inhibitor
in hormone sensitive, HER2 negative breast cancer can form the basis for a trial with this drug combination in hormone
sensitive rare ovarian cancer. The aim is to increase the response rate to aromatase inhibitors and the duration of response in
this study population with limited therapeutic options, monitor the quality of life and explore the (epi)genomic signatures that
correlate with response or endocrine resistance.